Illumina, Inc. $ILMN Position Lessened by Assenagon Asset Management S.A.

Key Points

• Assenagon Asset Management reduced its Illumina position by 41.5% in the third quarter, selling 58,145 shares and retaining 81,858 shares valued at approximately $22.4 million.
• Illumina reported quarterly earnings of $1.31 per share, exceeding estimates of $1.23, while revenue rose 9.4% year over year to $1.16 billion. Institutional investors own 89.42% of the company, though insiders sold more than 2 million shares during the quarter.
• Analyst sentiment remains mixed: Illumina has a consensus “Hold” rating and an average price target of $225.94, compared with the stock’s reported price of $262.54.

Assenagon Asset Management S.A. trimmed its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 41.5% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 81,858 shares of the life sciences company's stock after selling 58,145 shares during the period. Assenagon Asset Management S.A. owned approximately 0.05% of Illumina worth $22,403,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. BlackRock Inc. bought a new stake in Illumina in the 2nd quarter valued at about $3,374,423,000. WCM Investment Management LLC lifted its stake in Illumina by 45.5% during the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company's stock valued at $715,579,000 after acquiring an additional 1,851,848 shares in the last quarter. Primecap Management Co. CA purchased a new stake in shares of Illumina in the second quarter valued at about $617,981,000. Ninety One UK Ltd raised its holdings in shares of Illumina by 37,920.0% in the third quarter. Ninety One UK Ltd now owns 1,359,974 shares of the life sciences company's stock valued at $372,198,000 after purchasing an additional 1,356,397 shares during the last quarter. Finally, Jupiter Topco LLC bought a new position in shares of Illumina during the second quarter valued at about $358,652,000. Institutional investors own 89.42% of the company's stock.

Insider Buying and Selling

In other Illumina news, Director Keith Meister sold 457,858 shares of the stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the completion of the transaction, the director directly owned 2,372,694 shares of the company's stock, valued at approximately $474,776,069.40. This represents a 16.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 2,061,850 shares of company stock valued at $436,479,102 in the last quarter. 2.90% of the stock is currently owned by corporate insiders.

Illumina Stock Performance

NASDAQ ILMN opened at $262.54 on Monday. The business's fifty day moving average is $234.53 and its 200-day moving average is $186.47. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. The stock has a market capitalization of $39.64 billion, a price-to-earnings ratio of 48.98, a PEG ratio of 3.72 and a beta of 1.41. Illumina, Inc. has a one year low of $94.00 and a one year high of $309.35.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.23 by $0.08. The company had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The firm's revenue for the quarter was up 9.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Equities research analysts predict that Illumina, Inc. will post 5.36 EPS for the current year.

Analyst Ratings Changes

Several research firms recently weighed in on ILMN. Deutsche Bank Aktiengesellschaft cut shares of Illumina to a "hold" rating in a report on Wednesday, August 5th. Sanford C. Bernstein reiterated a "market perform" rating and issued a $215.00 price objective on shares of Illumina in a research note on Friday, July 31st. JPMorgan Chase & Co. lifted their target price on shares of Illumina from $220.00 to $230.00 and gave the stock an "overweight" rating in a research report on Friday, July 31st. Citigroup boosted their target price on Illumina from $95.00 to $113.00 and gave the stock a "sell" rating in a research note on Monday, August 3rd. Finally, Royal Bank Of Canada upped their target price on Illumina from $230.00 to $310.00 and gave the company an "outperform" rating in a report on Monday, October 5th. Ten research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Illumina has a consensus rating of "Hold" and a consensus target price of $225.94.

Illumina Profile

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company's offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.